search icon
  • What's New in Practice Management & Payment

    CMS: New Quality Payment Program Resources Available

    CMS will be hosting a webinar on Physician Compare

    MIPS 2017: Important Dates & Information

    New CPT® Modifier for Telemedicine Services

    CCHP: State Telehealth Laws and Reimbursement Policies

  • Upcoming Meetings

    IDWeek 2017 logo

The HIV Medicine Association is an organization of medical professionals who practice HIV medicine. We represent the interests of our patients by promoting quality in HIV care and by advocating for policies that ensure a comprehensive and humane response to the AIDS pandemic informed by science and social justice.

  • Policy News

    3/31/2017

    IDSA Leads Support for READI Act (PDF)

    IDSA and over forty other organizations representing healthcare providers, hospitals, pharmacists, scientists and microbiologists, industry, public health experts, patients and advocates expressed support for the Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act.

  • Breaking News and Alerts

    4/28/2017 2:55:09 PM

    U.S.-licensed yellow fever vaccine supply to be depleted by mid-2017

    CDC HAN Alert The Centers for Disease Control and Prevention outlines a plan to ensure a continuous yellow fever vaccine supply in the United States following the anticipated depletion of the U.S.-licensed YF-VAX® yellow fever vaccine in mid-2017, according to a Morbidity and Mortality Weekly Report published April 28, 2017.   In 2016, a manufacturing issue at Sanofi Pasteur limited the production of YF-VAX, and no yellow fever vaccine is expected to be available by mid-2017. YF-VAX is the only yellow fever vaccine licensed for use in the United States and is distributed to approximately 4,000 clinic sites. Because yellow fever is a potentially serious disease, CDC and Sanofi Pasteur collaborated on a plan to distribute limited quantities of Stamaril yellow fever vaccine to prevent people from becoming infected by the virus until production of YF-VAX resumes at a new facility in 2018. Stamaril is manufactured by Sanofi Pasteur in France and distributed in more than 70 countries. In October 2016, the U.S. Food and Drug Administration authorized an Expanded Access Investigational New Drug protocol that allows for the distribution of Stamaril® to designated U.S. clinic sites until YF-VAX production resumes. To ensure broad accessibility to limited quantities of the Stamaril vaccine, Sanofi Pasteur and CDC targeted clinic sites that administered a high volume of yellow fever vaccine to international travelers in 2016 or can provide coverage to an area of geographic need.  Based on these criteria, Sanofi Pasteur identified approximately 250 U.S. clinics to distribute Stamaril. This is a significant decrease from the approximately 4,000 clinic sites that distribute YF-VAX. When YF-VAX is no longer available, CDC will publish a list of clinic sites offering Stamaril at http://wwwnc.cdc.gov/travel/yellow-fever-vaccination-clinics/search. Healthcare providers and travelers can find more information about staying healthy while traveling at http://wwwnc.cdc.gov/travel. For yellow fever vaccine shortage and drug information, visit Sanofi Pasteur at http://www.sanofipasteur.us/vaccines/yellowfevervaccine.   ###   U.S. Department of Health and Human Services   CDC works 24/7 protecting America’s health, safety and security. Whether diseases start at home or abroad, are curable or preventable, chronic or acute, stem from human error or deliberate attack, CDC is committed to respond to America’s most pressing health challenges.

    4/10/2017 12:24:52 PM

    FDA approves two hepatitis C drugs for pediatric patients

    The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults.

    4/4/2017 3:21:04 PM

    CDC: About 1 in 10 U.S. pregnant women with confirmed Zika infection had a fetus or baby with birth defects in 2016

    Of the 250 pregnant women who had confirmed Zika infection in 2016, 24 – or about 1 in 10 of them – had a fetus or baby with Zika-related birth defects, according to a new Vital Signs report from the Centers for Disease Control and Prevention (CDC). This report is the first to provide the analysis of a subgroup of pregnant women in the U.S. with clear, confirmed test results of Zika virus infection.

    3/27/2017 12:24:20 PM

    CDC Updates Specimen Collection, Shipping, and Testing Guidance for Suspected Acute Flaccid Myelitis (AFM) Cases

    Despite extensive pathogen-specific testing of many specimens since 2014, CDC and others have not identified an etiology for the AFM cases. Therefore, CDC will no longer perform clinical diagnostics for enteroviruses or metagenomic sequencing on specimens collected from suspect cases of AFM.

    3/27/2017 12:10:57 PM

    Information for Healthcare Personnel Potentially Exposed to Hepatitis C Virus (HCV): Recommended Testing and Follow-up

    Exposure to viral hepatitis has long been recognized as an occupational risk for healthcare personnel, with recommendations previously established for the management of occupational exposures to hepatitis C virus (HCV). 

    3/10/2017 12:01:56 PM

    CDC adds 4 countries to interim travel guidance related to Zika virus

    CDC is working with other public health officials to monitor for ongoing spread of Zika virus‎. Today, CDC posted a Zika virus travel notice for Angola, Guinea-Bissau, Maldives and Solomon Islands. . 

    2/2/2017 3:52:05 PM

    New FDA Drug Safety Communication on chlorhexidine gluconate - Drug Information Update

    New FDA Drug Safety Communication on chlorhexidine gluconate- Drug Information Update

    1/17/2017 5:07:35 PM

    FDA MedWatch - ED-3490TK Video Duodenoscope by Pentax: FDA Safety Communication - UPDATE

    FDA Alert

  • News from IDSA and the Journals

    IDSA News: April 2017

    Read More >>

| IDSA | Contact Us

© Copyright HIVMA 2017 HIV Medicine Association

Full Site Mobile Site